linjc16/ctgov huggingface dataset:
Histopathological Examination of Iris Tissue in Buphthalmos

Study Overview
=================
Brief Summary
-----------------
To revise the etiology of the primary congenital glaucoma in some infants.

Detailed Description
-----------------
Combined trabeculotomy trabeculectomy with mitomycin C was done in 11 eyes. Histopathological examination of the peripheral iris tissue specimen was done in all cases.

Official Title
-----------------
Histopathological Examination of Iris Tissue in Buphthalmos

Conditions
-----------------
Iris Disease

Intervention / Treatment
-----------------
* Procedure: Combined trabeculotomy trabeculectomy with mitomycin C


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: infants under age of 2 years 1ery glaucoma Exclusion Criteria: infants more than 2 years 2ery glaucoma previous glaucoma surgery
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: isolated trabeculodysgensis<br>etiology of primary congenital glaucoma | Procedure: Combined trabeculotomy trabeculectomy with mitomycin C<br>* Combined trabeculotomy trabeculectomy with mitomycin C with histopathological examination of the peripheral iris tissue specimen of all cases<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fibrovascular membrane over iris surface | angle closure by a fibrovascular tissue proliferation over the trabecular meshwork in the anterior chamber angle. | 6 month |
Vitamin and Asthma Study

Study Overview
=================
Brief Summary
-----------------
The study looks at how vitamin D supplement will improve the severity of asthma and lung function as well as biomarkers in asthmatic children.

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: Vitamin D


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: History of asthma (under control)otherwise in good general health Exclusion Criteria: Poorly controlled asthma Taking daily multivitamin or vitamin D supplementation Taking oral steroid medication History of bronchopulmonary dysplasia or chronic lung disease, extreme prematurity, congenital heart disease, significant renal dysfunction or primary kidney disease, endocrinologic abnormalities of calcium metabolism or parathyroid disorders

Ages Eligible for Study
-----------------
Minimum Age: 7 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 2000 IU vitamin D Daily<br> | Drug: Vitamin D<br>* Vitamin D 2000 IU daily pill Vitamin D 400 IU daily pill<br>|
| Placebo Comparator: 400 IU Vitamin D pill<br> | Drug: Vitamin D<br>* Vitamin D 2000 IU daily pill Vitamin D 400 IU daily pill<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Pulmonary Function Test (PFT) after vitamin D supplementation |  | 4 weeks | 
| Change in Asthma Control Test (ACT) scores after vitamin D supplementation |  | 4-week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma, Pulmonary Function Test, Vitamin D
Bariatric Surgery and Pharmacokinetics of Ibuprofen

Study Overview
=================
Brief Summary
-----------------
Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on ibuprofen are investigated.

Official Title
-----------------
Bariatric Surgery and Pharmacokinetics Ibuprofen: BAR-MEDS Ibuprofen

Conditions
-----------------
Obesity, Morbid

Intervention / Treatment
-----------------
* Drug: Ibuprofen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway Being a Norwegian citizen Exclusion Criteria: Having previously undergone resections in the GI-tract

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Ibuprofen|Patients are tested for their normal prescription ibuprofen medication|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ibuprofen concentration in blood serum (area under curve (AUC)) |  | From baseline to 1 year postoperatively | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bariatric surgery, Gastrointestinal tract, Biological availability, Pharmacokinetics, Ibuprofen
Determine the Effect of Prone Positioning in Adults With ARDS by Electrical Impedance Tomography

Study Overview
=================
Brief Summary
-----------------
determine the effect of prone positioning on ventilation and perfusion distribution in adults with acute respiratory distress syndrome by electrical impedance tomography

Detailed Description
-----------------
By intravenous injection of a small amount of normal saline, electrical impedance tomography enables evaluation of the pulmonary blood flow. EIT might be helpful in establishing the hypoxemia etiology at bedside via combining regional ventilation and perfusion information. The objective of this study was to describe the physiological effects of prone position on respiratory mechanics, ventilation and pulmonary perfusion in patients with ARDS.

Official Title
-----------------
Determine the Effect of Prone Positioning on Lung Ventilation and Perfusion Distribution in Adults With Acute Respiratory Distress Syndrome by Electrical Impedance Tomography

Conditions
-----------------
ARDS, Prone Position, Electrical Impedance Tomography

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who were undergoing mechanical ventilation with moderate-to-severe ARDS (defined as a Pao2:Fio2 ratio < 150 mm Hg with a positive end-expiratory pressure ≥ 5 cm of water, and an Fio2 of ≥ 0.6) according to the Berlin definition Exclusion Criteria: contraindications to the use of EIT (e.g., presence of pacemaker or chest surgical wounds dressing)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess regional distribution of pulmonary perfusion | To evaluate the effect of prone positon on pulmonary blood flow distribution. | within 24 hours | 
| Assess regional distribution of pulmonary ventilation | To evaluate the effect of prone positon on pulmonary vetilation distribution. | within 24 hours | 
| Assess oxygenation status | To evaluate the effect of prone position by assessing regional distribution of pulmonary perfusion based on indicator dilution and changes at different points in time during varying states of regional ventilation will be evaluated. | within 24 hours |
LARS in Ovarian Cancer Patients

Study Overview
=================
Brief Summary
-----------------
Background: Low anterior resection syndrome (LARS) is a common functional disorder after low anterior resection impacting quality of life. Data on LARS derives nearly exclusively from rectal cancer studies. Therefore, the study was designed to assess LARS in advanced epithelial ovarian cancer (EOC) patients, who underwent rectal resection and to compare it with a female rectal cancer cohort. Methods: A cross-sectional multi-centre analysis was performed for female patients suffering from either rectal or EOC who received a low anterior resection as part of their therapy regimen. None of the patients received pre- or postoperative radiotherapy. LARS was defined by using the validated LARS score and its severity was divided into no, minor and major LARS.

Official Title
-----------------
Low Anterior Resection Syndrome (LARS) in Ovarian Cancer Patients - a Multi-centre Comparative Analysis.

Conditions
-----------------
Low Anterior Resection Syndrome

Intervention / Treatment
-----------------
* Other: low anterior resection syndrome evaluation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: low anterior resection because of ovarian or rectal cancer Exclusion Criteria: neoadjuvant or adjuvant radiotherapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>rectal cancer patients | Other: low anterior resection syndrome evaluation<br>* evaluation of postoperative functional bowel outcome<br>|
| 2<br>ovarian cancer patients | Other: low anterior resection syndrome evaluation<br>* evaluation of postoperative functional bowel outcome<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| functional bowel outcome after low anterior resection | low anterior resection syndrome score, questionnaire via telephone call or personal contact | 1 year |
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)

Study Overview
=================
Brief Summary
-----------------
Vienna Consensus has identified 10% damage rate after ICSI as a competency value. Despite the highest quality embryologists doing ICSI, degeneration sometimes occurs due to oocyte factors such as the fragile membrane, etc. Latrunculin A serves to facilitate spindle or pronuclear transfer procedures helping to reduce the damage rate with no harm reported. Using Latrunculin A during ICSI could serve to rescue some oocytes from the degeneration allowing for more chances of viable zygotes,

Official Title
-----------------
Latrunculin A Supplementation to ICSI Handling Medium

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Other: Medium Supplemented with Latrunculin A


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ICSI participants Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 42 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Handling Medium Supplemented with Latrunculin A<br> | Other: Medium Supplemented with Latrunculin A<br>* A medium with in-house supplementation of Latrunculin A to decrease oocyte degeneration after ICSI and improve the survival rate<br>|
| No Intervention: Handling Medium as it is.<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| oocyte survival rate |  | 6 days of culture | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fertilization rate |  | 6 days of culture | 
| Blastocyst formation rate |  | 6 days of culture | 
| Blastocyst quality rate |  | 6 days of culture | 
| Clinical pregnancy rate |  | three months | 
| Implantation rate |  | 7 weeks | 
| Ongoing pregnancy rate |  | 12 weeks |
Tracking Breathing During Sleep With Non-contact Sensors

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the feasibility of tracking breathing during sleep with non-contact sensors (for example, microphones or wireless movement sensors). The investigators will use the data collected with these sensors to develop algorithms for tracking breathing during sleep. The investigators will assess the performance of the algorithms by comparing automatic output against manually-generated labels.

Detailed Description
-----------------
Subjects will be asked to place non-contact sensors (for example, ambient microphones, wireless movement sensors) in their home sleep environment. No sensors will be attached to or otherwise in contact with the subject's body. The subjects will start the data collection before they fall asleep, and stop the data collection the next morning when they wake. The subjects will then return the sensors to the investigator for analysis. The investigators will study the data and associated manual labeling. The investigators will develop algorithms that use statistical and machine-learning methods to train computer models designed to track breathing automatically. The investigators will compare the automatic output against manually generated labels to determine breath-tracking accuracy.

Official Title
-----------------
Tracking Breathing During Sleep With Non-contact Sensors

Conditions
-----------------
Sleep Apnea Syndromes, Snoring

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 21-89 No self-reported sleep breathing problems Exclusion Criteria: Positive diagnosis for sleep breathing problem (e.g., obstructive sleep apnea)

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| At-Home<br>Overnight sleep at home | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Breathing sounds are evident in overnight audio recordings | This study aims to track breathing during sleep using a high-quality audio interface. Our primary objective is to determine if quiet breathing sounds are visible (in the spectral domain) to trained human labelers. | Night of recording | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sleep apnea, snoring
Observational Study on Anti-Tat Immune Response in HIV-1-infected HAART-treated Adult Subjects

Study Overview
=================
Brief Summary
-----------------
The present study is designed as a prospective observational study directed at evaluating the frequency, magnitude, quality and persistence (primary endpoint) of the anti-Tat immune response in highly active antiretroviral therapy (HAART)-receiving HIV-1 infected individuals, and to prospectively evaluate the immunological, virological and clinical outcome of anti-Tat positive versus anti-Tat negative subjects under successful HAART (secondary endpoint), in order to determine the impact of anti-Tat immunity on HIV disease progression as well as the potential use of anti-Tat immune response assessment for the clinical and therapeutic management of HAART-treated infected patients. This survey provided important information for the design, planning and conduction of future therapeutic vaccine trials based on the HIV-1 Tat protein in HAART-treated patients.

Official Title
-----------------
Observational Study With Additional Diagnostic Procedures on Anti-Tat Immune Response in HIV-1-infected HAART-treated Adult Subjects

Conditions
-----------------
HIV Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of HIV-1 infection To be under successful HAART treatment with plasma viremia <50 copies/ml in the last 6 months prior to initiation of the study, without a history of virologic rebound Known CD4+ T cells nadir Age ≥ 18 years old Signed informed consent Exclusion Criteria: Current therapy with immunomodulators or immunosuppressive drugs, or chemotherapy for neoplastic disorders Concomitant treatment for HBV or HCV infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of anti-Tat antibodies in sera of subjects, and of the proliferative response (CFSE) and the production of γIFN, IL-4 and IL-2 (Elispot) by peripheral blood mononuclear cells (PBMC) in response to Tat. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The decline of CD4+ T cell counts, the increase of HIV plasma viral load or the occurrence of AIDS-defining events were assessed to determine progression to disease. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV, HAART
Bronchial Response to Mannitol and Inflammation in Steroid Naive Asthmatics.

Study Overview
=================
Brief Summary
-----------------
Study on the relationship between the response of the airways to a bronchial provocation test with mannitol and the degree of airway inflammation in asthma patients.

Detailed Description
-----------------
Study on the relationship between the response of the airways to a bronchial provocation test with mannitol and the degree of airway inflammation in asthma patients.

Official Title
-----------------
Bronchial Response to Mannitol and Inflammation in Steroid Naive Asthmatics

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Procedure: mannitol test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Steroid naive asthma. Non-smoker Exclusion Criteria:

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: mannitol test|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Examination of Implant´s Safety in an Electronic and Magnetic Field Environment

Study Overview
=================
Brief Summary
-----------------
The number of active electrical cardiac implants such as internal cardioverter defibrillators (ICDs), pacemakers or cardiac contractility modules (CCM) has significantly risen over the last two decades. This has been paralleled by an increase in the number of sources of electromagnetic fields in daily life and occupational circumstances. To date it remains unclear whether patients are at risk of device failure when being subjected to these fields. There are currently no general guidelines available to help clinicians informing their patients about safety levels and behavior around these electromagnetic fields. This study aims to identify the thresholds of safe use of these devices and potential failures under worst-case conditions in 50/60 Hz fields (i.e. power line frequency). Device implanted patients will be exposed to electric, magnetic and combined fields of different intensity at various device programming (e.g. nominal and maximum sensitivity). The results will show whether patients are safe in public or occupational environments, which medical relevant disturbances can occur and if a correlation exists between disturbances and device type or patients physique.

Official Title
-----------------
Study of Provocation Concerning Implants´Safety in Electronic and Magnetic Fields in Their Environment

Conditions
-----------------
Disorder of Cardiac Pacemaker System, Disorder of Implantable Defibrillator, Cardiac Arrhythmia

Intervention / Treatment
-----------------
* Device: Magnetic and electric field´s impact on the implant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: men and women between 18 and 80 years Implantation of a Pacemaker (SM)-/ ICD-assembly at least four weeks ago signed informed consent Exclusion Criteria: enduring addiction of implant thyroid disease electrolyte imbalance on the trial day pregnancy and breastfeeding acute myocardial infarction (<30 days) Comorbidity, which complicates an emergency assistance, e.g. morbus bechterew, glaucoma, micturition disturbance

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cardiac pacemaker<br> | Device: Magnetic and electric field´s impact on the implant<br>* Examination of magnetic and electric field's impact on the implant regarding: stability detection threshold using different strength of magnetic and electric field<br>* Other names: Examination;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Interference threshold of the device in electromagnetic fields in V/m and/or µT |  | for every patient during one ambulant visit about 1 hour study examination |